NASDAQ:LMAT - LeMaitre Vascular Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$27.36 +0.32 (+1.18 %)
(As of 11/16/2018 02:51 PM ET)
Previous Close$27.04
Today's Range$26.86 - $27.62
52-Week Range$25.63 - $41.28
Volume50,480 shs
Average Volume107,029 shs
Market Capitalization$518.34 million
P/E Ratio31.81
Dividend Yield1.06%
Beta0.99
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.

Receive LMAT News and Ratings via Email

Sign-up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LMAT
Previous Symbol
CUSIPN/A
Phone781-221-2266

Debt

Debt-to-Equity RatioN/A
Current Ratio5.93
Quick Ratio4.30

Price-To-Earnings

Trailing P/E Ratio31.81
Forward P/E Ratio26.82
P/E Growth2.14

Sales & Book Value

Annual Sales$100.87 million
Price / Sales5.31
Cash Flow$1.1391 per share
Price / Cash24.02
Book Value$6.40 per share
Price / Book4.28

Profitability

EPS (Most Recent Fiscal Year)$0.86
Net Income$17.17 million
Net Margins20.52%
Return on Equity18.07%
Return on Assets15.79%

Miscellaneous

Employees423
Outstanding Shares19,580,000
Market Cap$518.34 million
OptionableOptionable

LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions

What is LeMaitre Vascular's stock symbol?

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular declared a quarterly dividend on Monday, October 8th. Stockholders of record on Tuesday, November 20th will be paid a dividend of $0.07 per share on Thursday, December 6th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date is Monday, November 19th. View LeMaitre Vascular's Dividend History.

How will LeMaitre Vascular's stock buyback program work?

LeMaitre Vascular announced that its Board of Directors has authorized a share repurchase program on Friday, July 28th 2017, which authorizes the company to buyback $7,500,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 1.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board of directors believes its shares are undervalued.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular Inc (NASDAQ:LMAT) issued its earnings results on Friday, October, 5th. The medical instruments supplier reported $0.21 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.21 by $0.00. The medical instruments supplier earned $24.17 million during the quarter, compared to analysts' expectations of $26.06 million. LeMaitre Vascular had a return on equity of 18.07% and a net margin of 20.52%. View LeMaitre Vascular's Earnings History.

When is LeMaitre Vascular's next earnings date?

LeMaitre Vascular is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for LeMaitre Vascular.

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular updated its FY 2018 earnings guidance on Monday, October, 8th. The company provided EPS guidance of $1.01-1.03 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.07. The company issued revenue guidance of $102.8-103.6 million, compared to the consensus revenue estimate of $107.15 million.

What price target have analysts set for LMAT?

6 Wall Street analysts have issued 1 year target prices for LeMaitre Vascular's stock. Their forecasts range from $32.00 to $45.00. On average, they expect LeMaitre Vascular's stock price to reach $36.50 in the next year. This suggests a possible upside of 33.6% from the stock's current price. View Analyst Price Targets for LeMaitre Vascular.

What is the consensus analysts' recommendation for LeMaitre Vascular?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LeMaitre Vascular.

What are Wall Street analysts saying about LeMaitre Vascular stock?

Here are some recent quotes from research analysts about LeMaitre Vascular stock:
  • 1. According to Zacks Investment Research, "LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. " (10/10/2018)
  • 2. Barrington Research analysts commented, "We are upgrading our investment rating on LMAT shares to OUTPERFORM (from MARKET PERFORM previously). We think that Friday’s trading action that resulted in a 20.7% downdraft in LMAT’s market value was overdone and provides investors with an attractive entry point. We have always liked this business and its leadership but had found stock valuation a recurring challenge when assessing this idea – until Friday, that is. Our price target is $34. We arrive at our target by attaching a 20x multiple to our 2019 adjusted EBITDA estimate. We assume approximately $60 million in net cash 12 months from now." (10/8/2018)

Has LeMaitre Vascular been receiving favorable news coverage?

Media headlines about LMAT stock have trended positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. LeMaitre Vascular earned a news sentiment score of 2.1 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future.

Who are some of LeMaitre Vascular's key competitors?

Who are LeMaitre Vascular's key executives?

LeMaitre Vascular's management team includes the folowing people:
  • Mr. George W. LeMaitre, Chairman & CEO (Age 53)
  • Mr. David B. Roberts, Pres & Director (Age 54)
  • Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 53)
  • Mr. Trent G. Kamke, Sr. VP of Operations (Age 47)
  • Dr. George D. LeMaitre, Founder and Chairman of Scientific Advisory Board (Age 84)

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.00%), Conestoga Capital Advisors LLC (8.32%), Dimensional Fund Advisors LP (5.21%), Epoch Investment Partners Inc. (4.26%), Thomson Horstmann & Bryant Inc. (2.02%) and AWM Investment Company Inc. (1.69%). Company insiders that own LeMaitre Vascular stock include David B Roberts, George W Lemaitre, Joseph P Pellegrino Jr, Lawrence J Jasinski, Michael H Thomas, Michael T Wijas, Peter R Gebauer and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular.

Which major investors are selling LeMaitre Vascular stock?

LMAT stock was sold by a variety of institutional investors in the last quarter, including Epoch Investment Partners Inc., Citadel Advisors LLC, Renaissance Technologies LLC, Panagora Asset Management Inc., AQR Capital Management LLC, AWM Investment Company Inc., Strs Ohio and Royce & Associates LP. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, Joseph P Pellegrino Jr, Michael H Thomas and Trent G Kamke. View Insider Buying and Selling for LeMaitre Vascular.

Which major investors are buying LeMaitre Vascular stock?

LMAT stock was acquired by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, BlackRock Inc., Summit Creek Advisors LLC, Wells Fargo & Company MN, Bahl & Gaynor Inc., Russell Investments Group Ltd., Wasatch Advisors Inc. and Kaizen Advisory LLC. View Insider Buying and Selling for LeMaitre Vascular.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is LeMaitre Vascular's stock price today?

One share of LMAT stock can currently be purchased for approximately $27.32.

How big of a company is LeMaitre Vascular?

LeMaitre Vascular has a market capitalization of $518.34 million and generates $100.87 million in revenue each year. The medical instruments supplier earns $17.17 million in net income (profit) each year or $0.86 on an earnings per share basis. LeMaitre Vascular employs 423 workers across the globe.

What is LeMaitre Vascular's official website?

The official website for LeMaitre Vascular is http://www.lemaitre.com.

How can I contact LeMaitre Vascular?

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266.


MarketBeat Community Rating for LeMaitre Vascular (NASDAQ LMAT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  317 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  548
MarketBeat's community ratings are surveys of what our community members think about LeMaitre Vascular and other stocks. Vote "Outperform" if you believe LMAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel